Gate Neurosciences Overview
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
Gate Neurosciences General Information
Description
Developer of neuronal therapeutics designed to treat neuropsychiatric and cognitive diseases. The company's therapies are designed to rapidly and safely enhance neuroplasticity and strengthen neuronal connections to restore healthy brain function its drug candidate is currently in Phase 2b clinical trials for Major Depressive Disorder, enabling patients and doctors to have a proper way to treat central nervous system conditions by creating safe, potent, and rapid-acting therapies.
Contact Information
Website
www.gateneuro.comCorporate Office
- 1210 Waterway Boulevard
- Indianapolis, IN 46202
- United States
Corporate Office
- 1210 Waterway Boulevard
- Indianapolis, IN 46202
- United States
Gate Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 27-May-2025 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 05-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 09-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 29-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 11-Jun-2019 | $4.5M | $4.5M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Pre-Clinical Trials |
Gate Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Gate Neurosciences Signals
Gate Neurosciences Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| BioCrossroads | Venture Capital | Minority | ||
| Evolution VC Partners | Venture Capital | Minority | ||
| Innoviva | Holding Company | Minority | ||
| Luson BioVentures | Venture Capital | Minority |
Gate Neurosciences Acquisitions (1)
Gate Neurosciences’s most recent deal was a Merger/Acquisition with Boost Neuroscience. The deal was made on 31-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Boost Neuroscience | 31-Jan-2025 | Merger/Acquisition | Drug Discovery |
Gate Neurosciences FAQs
-
Where is Gate Neurosciences headquartered?
Gate Neurosciences is headquartered in Indianapolis, IN.
-
What is the size of Gate Neurosciences?
Gate Neurosciences has 17 total employees.
-
What industry is Gate Neurosciences in?
Gate Neurosciences’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Gate Neurosciences a private or public company?
Gate Neurosciences is a Private company.
-
What is Gate Neurosciences’s current revenue?
The current revenue for Gate Neurosciences is .
-
How much funding has Gate Neurosciences raised over time?
Gate Neurosciences has raised $45.6M.
-
Who are Gate Neurosciences’s investors?
AbbVie Ventures, BioCrossroads, Evolution VC Partners, Innoviva, and Luson BioVentures are 5 of 7 investors who have invested in Gate Neurosciences.
-
When was Gate Neurosciences acquired?
Gate Neurosciences was acquired on 27-May-2025.
-
Who acquired Gate Neurosciences?
Gate Neurosciences was acquired by Syndeio Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process